AbbVie Inc (ABBV)

Pretax margin

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Earnings before tax but after interest (EBT) (ttm)	US$ in thousands	6,240,000	7,996,000	10,443,000	9,015,000	13,468,000	14,772,000	14,062,000	14,043,000	12,982,000	7,203,000	6,011,000	4,159,000	3,392,000	7,975,000	7,481,000	8,980,000	8,426,000	2,979,000	3,739,000	4,944,000
Revenue (ttm)	US$ in thousands	54,318,000	55,138,000	56,023,000	56,741,000	58,054,000	57,819,000	57,349,000	56,725,000	56,197,000	55,169,000	53,729,000	50,195,000	45,804,000	40,650,000	36,227,000	34,057,000	33,266,000	32,867,000	32,624,000	32,647,000
Pretax margin		11.49%	14.50%	18.64%	15.89%	23.20%	25.55%	24.52%	24.76%	23.10%	13.06%	11.19%	8.29%	7.41%	19.62%	20.65%	26.37%	25.33%	9.06%	11.46%	15.14%

December 31, 2023 calculation

Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $6,240,000K ÷ $54,318,000K
= 11.49%

The pretax margin of Abbvie Inc has shown a downward trend over the past few quarters. It decreased from 23.21% in Q4 2022 to 11.51% in Q4 2023. This may indicate a decline in the company's ability to generate profits before taxes relative to its total revenue or operating costs. The pretax margin has fluctuated throughout the quarters but generally remained above 10%, reflecting the company's ability to maintain profitability. Further analysis is recommended to understand the factors driving these changes and their potential impact on Abbvie's financial performance.